Esophageal Tumor Thickness on Computed Tomography as a Predictor of Residual Tumor in Esophageal Adenocarcinoma Following Preoperative Chemoradiation by Francis, A.M, Correa, A.M, Betancourt-Cuellar, S.L, Kim, J.Y, Sepesi, B, Ajani, J.A, Komaki, R, Erasmus, J, Maru, D.M, Mehran, R.J, Rice, D.C, Roth, J.A, Vaporciyan, A.A, Walsh, G.L, Hofstetter, W.L, Swisher, S.G

Get full text

ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients by Ajani, J.A., Wang, X., Song, S., Suzuki, A., Taketa, T., Sudo, K., Wadhwa, R., Hofstetter, W.L., Komaki, R., Maru, D.M., Lee, J.H., Bhutani, M.S., Weston, B., Baladandayuthapani, V., Yao, Y., Honjo, S., Scott, A.W., Skinner, H.D., Johnson, R.L., Berry, D.

Request full text

PND11 - INDIRECT TREATMENT COMPARISON OF AVXS-101 TO NUSINERSEN FOR THE TREATMENT OF TYPE 1 SPINAL MUSCULAR ATROPHY by Lorenzi, M, Dabbous, O, Jansen, JP, Maru, B, Sproule, D.M., Feltner, D, White, C

Get full text

PRO2 THE VALUE OF ONASEMNOGENE ABEPARVOVEC GENE-REPLACEMENT THERAPY IN IMPROVING SURVIVAL AND MOTOR FUNCTION AND DECREASING VENTILATORY SUPPORT AND HOSPITALIZATION CONTRASTED TO NA... by Dabbous, O., Sproule, D.M., Feltner, D.E., Ogrinc, F.G., Menier, M., Droege, M., Maru, B., Khan, F., Arjunji, R.

Get full text

ND2 COST-UTILITY ANALYSIS OF SINGLE DOSE GENE-REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 COMPARED TO CHRONIC NUSINERSEN TREATMENT by Malone, D., Dean, R., Miller, B., Arjunji, R., Feltner, D.E., Sproule, D.M., Jensen, I.S., Maru, B., Dabbous, O.

Get full text

PND9 EVENT-FREE SURVIVAL AND MOTOR MILESTONE ACHIEVEMENT FOLLOWING AVXS-101 AND NUSINERSEN INTERVENTIONS CONTRASTED TO NATURAL HISTORY FOR TYPE I SPINAL MUSCULAR ATROPHY PATIENTS by Dabbous, O., Sproule, D.M., Feltner, D.E., Ogrinc, F.G., Menier, M., Droege, M., Maru, B., Khan, F., Arjunji, R.

Get full text

PSY16 - HEALTH OUTCOME IMPROVEMENTS IN SPINAL MUSCULAR ATROPHY TYPE 1 PATIENTS WITH AVXS-101 GENE REPLACEMENT THERAPY by Al-Zaidy, S., Pickard, A.S., Kotha, K., Alfano, L., Lowes, L., Paul, G., Church, K., Lehman, K., Sproule, D.M., Dabbous, O., Maru, B., Berry, K., Arnold, W.D., Kissel, J.T., Mendell, J.R., Shell, R.

Get full text

CM4 TIME TO TREATMENT EFFECT, EVENT-FREE SURVIVAL, AND MOTOR MILESTONE ACHIEVEMENT IN TYPE I SPINAL MUSCULAR ATROPHY PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC (AVXS-101) OR NU... by Dabbous, O., Sproule, D.M., Feltner, D.E., Ogrinc, F.G., Menier, M., Droege, M., Maru, B., Khan, F., Novack, A., Arjunji, R.

Get full text

PBI1 THE VALUE OF ONASEMNOGENE ABEPARVOVEC (AVXS-101) AS A COST-EFFECTIVE GENE REPLACEMENT THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1 IN IMPROVING SURVIVAL, HEALTHCARE RESOURCE UTI... by Malone, D.C., Arjunji, R., Dean, R., Sproule, D.M., Feltner, D.E., Droege, M., Khan, F., Maru, B., Jensen, I., Dabbous, O.

Get full text

Australian rangelands as complex adaptive systems: A conceptual model and preliminary results by Gross, J.E., McAllister, R.R.J., Abel, N., Smith, D.M. Stafford, Maru, Y.

Get full text